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Ivermectin: Potential Repurposing 




Drug repositioning is a alternative strategy to discover and develop anticancer 
drugs based on identification of new mechanisms of actions and indications for 
existing compounds. Ivermectin belongs to the avermectin group of compounds, a 
series of 16-membered macrocyclic lactone moieties discovered in 1967 and FDA-
approved for human use since 1987. Ivermectin has since been used by millions of 
people worldwide, and have demonstrated a wide margin of clinical safety. Here we 
summarize the in vitro and in vivo evidence demonstrating ivermectin's potential 
as a multitargeting anticancer drug that exerts antitumor effects against different 
tumor types. Notably, the in vitro and in vivo antitumor activities of ivermectin are 
achieved at concentrations that can be clinically achieved based on human phar-
macokinetic studies done in the clinical studies. Moreover, repurposed ivermectin 
safety has been well established recently in clinical studies against COVID-19. 
Consequently, we believe that ivermectin is an excellent potential candidate drug 
that can be repurposed for cancer and deserves rigorous evaluation against a variety 
of cancers in well-designed clinical trials.
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1. Introduction
Avermectins are a complex of 16-membered macrocyclic lactones produced 
from soil fermentation of the actinomycete S. avermitilis [1, 2]. There exist eight 
avermectin compounds (A1a, A1b, A2a, A2b, B1a, B1b, B2a, and B2b), of which 
ivermectin is the most commonly employed due to its semi-synthetic mixture 
(80% B1a and 20% B1b), and its potent antiparasitic activity as well as its safety 
[3]. The family of compounds from which Ivermectin is derived was discovered 
by Nobel laureates Satoshi Omura and William Campbell in the 1970s. The chemi-
cal is effective against a wide number of parasites and arthropods - pinworms, 
mites, lice, heartworms and fleas in dogs, parasitic worms in pasture animals by 
disrupting the fluid exchange through the insect’s cell membrane, and in the past 
40 years, ivermectin has been used extensively for agriculture and veterinary 
purposes [4–7].
The success of ivermectin treatment as antiparasitic is due to its high affinity 
for the glutamate-gated chloride channels (Glu-Cl) present in parasite cells but 
absent in vertebrates. The ivermectin-channel-interaction prevents channel closure, 
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leading to plasma membrane hyperpolarization, paralyzing the target parasite’s 
pharyngeal and somatic muscles, triggering its death [2]. In addition to activat-
ing the Glu-Cl parasites channels, ivermectin acts as a dose-dependent positive 
allosteric regulator of several vertebrate ligand-gated channels, including the 
γ-aminobutyric acid type-A receptor (GABA receptor), glycine receptor, neuronal 
α7-nicotinic receptor, and purinergic P2X4 receptor. The effects of ivermectin 
over these receptors include the potentiation of agonist-induced currents at low 
concentrations and channel opening at higher concentrations [8]. However, 
GABA-sensitive neurons are protected by the blood–brain barrier within the central 
nervous system, protecting vertebrates against the potentially harmful effects of 
Ivermectin [3, 6].
2. Drug repurposing in cancer therapy
Effective, safe, and affordable cancer drugs are highly needed to reduce cancer 
mortality. The field of drug repurposing emerged in the early 1990s as an alter-
native to the conventional drug discovery model. This model entails targeting 
discovery and validation, lead identification by high-throughput screening, and 
lead optimization by medicinal chemistry. Drug repurposing surged to overcome 
the pharmaceutical industry’s limited productivity regarding the number of 
approved drugs concerning the long time and huge money required to develop a 
drug. Classical drug discovery requires an average of 15 years of research, whereas 
drug development by repurposing is portended to be cheaper, faster, and safer. The 
significant advantage of drug repurposing is that the pharmacokinetics, pharmaco-
dynamics, and toxicity profiles of drugs are, in general, well known; thus, its rapid 
translation into phase II and III clinical trials is feasible [9]. Among the different 
drugs currently studied under the focus of therapeutic repositioning, ivermectin 
is very promising. It has been shown to have antitumor effects in vitro and in vivo 
(Figure 1).
3.  Antitumor effects of Ivermectin-mechanisms of action and in vitro 
data
Ivermectin has demonstrated antitumor effects in different types of can-
cers. Among mechanisms of action reported, ivermectin interacts and affects 
the function of 1) mitochondrial I complex, the multidrug resistance protein 
(MDR), 2) RNA helicases, 3) the WNT-TCF pathway, 4) chloride channel 
receptor, 5) immunogenic cell death via ATP- and HMGB1, 6) PAK-1, 7,8) 
epigenetic signature and sel-renewal of stem cells [10]. Preclinical testing have 
demonstrated inhibition of cell growth, induction of apoptosis in different 
cancer cell lines and antitumor effects in murine models (Figure 1) [11–19]. 
The in vitro antitumor effects are observed at a median concentration of 5 μM 
(0.01–100 μM), which is clinically attainable according to the pharmacokinetic 
data in humans shown in Table 1. We present a review of the laboratory results 
of ivermectin on various cancer cell lines below.
3.1 Ovarian cancer
Ivermectin blocks the oncogenic kinase PAK1 in human ovarian cancer and in 
NF2-deficient Schwannoma cell lines to suppress their PAK1-dependent growth 
in cell culture at a half maximal inhibitory concentration (IC50) between 5 and 
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Figure 1. 
Cancer targets of ivermectin. 1. Decreasing the function of the mitochondrial complex I, Ivermectin, limits 
the electronic movement in the oxidative phosphorylation pathway that stimulates oxygen consumption rate 
to generate ATP for the cell. Low ATP levels are related to a failure in the P-glycoprotein pump to extrude 
chemotherapy drugs. Concomitantly there is a reduction in the phosphorylation levels of Akt, impacting 
the mitochondrial biogenesis process. Furthermore, alterations in the mitochondrial machinery are related 
to increased levels of reactive oxygen species that damage DNA. 2. Ivermectin limits the function of the 
RNA helicases NS3 and DDX23, both of which are related to ribosome biogenesis and post-transcriptional 
modifications, as well as with mRNA degradation. DDX23 acts as a promoter of miR-21, which is a well-
recognized stimulator of tumor progression. 3. The WNT-TCF pathway, involved in cancer progression and 
metastases, is inhibited by Ivermectin. Indeed, this compound represses AXIN2, LGR5, and ASCL2, all of 
them WNT-TCF targets. At the same time, it promotes the repressor of the WNT signaling FILIP1L. Both 
effects inhibit the ability of WNT-TCF to downregulate the tumor suppressor APC and limit the translocation 
of β–catenin to the nucleus for epithelial to mesenchymal transition in metastatic events. 4. Ivermectin acts 
as an ionophore by the up-regulation of chloride channels to generate apoptosis and osmotic cell death. 5. 
Ivermectin induces immunogenic cell death by stimulating an ATP- and HMGB1-enriched microenvironment, 
which promotes inflammation. This drug also increases ATP sensitivity and calcium signals in P2X membranal 
receptors, particularly P2X4 and P2X7, to induce ATP-dependent immune responses. 6. Ivermectin promotes 
the poly-ubiquitination of the kinase PAK1, which directs it to degradation in the proteasome. Defective PAK1, 
in turn, inhibits the Akt/mTOR pathway. At the same time, Ivermectin stimulates the expression of Beclin1 
and Atg5, both related to induction of autophagy. Particularly, Beclin1 increases the expression of the positive 
autophagy regulators Atg14L and Vps34 and reduces the negative regulator of apoptosis Bcl-2. Together, this 
generates autophagy and apoptosis. 7,8. Ivermectin modifies the epigenetic signature and the self-renewal activity 
in the malignant cell due to its ability to mimic the SIN3-interaction that binds to the PAH2 motif of the ca.
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20 μM [14]. PAK1 is involved in various signaling pathways that play an essential 
role in cytoskeletal dynamics, cell adhesion, migration, proliferation, apoptosis, 
and mitosis. It is required for the growth of approximately 70% of neoplasms [20]. 
Additionally, cancer stem-like cells derived from SKOV-3 cell line treated with 5 μM 
ivermectin showed a significant decrease in cell viability and clonogenic capacity. 
Also, the expression levels of Nanog, Sox2, and Oct4 are reduced after treatment 
with ivermectin 5 μM [11].
3.2 Breast cancer
Ivermectin inhibits the ATK/mTOR pathway in breast cancer cell lines by 
promoting ubiquitination of PAK1. Ivermectin disrupts the binding of PAK1 protein 
with AKT, and in turn hinders the phosphorylation and activation of AKT; result-
ing in AKT/mTOR pathway inactivation. These effects of ivermectin are observed 
at concentrations above 10 μM [15]. Additionally, ivermectin preferentially inhibits 
the viability of cancer stem-like cells enriched populations (CD44+/ CD24−) in the 
range of 0.2–8 μM via reducing the expression of maintenance of the pluripotency 
and self-renewal markers Nanog, Oct4, and Sox2 at both mRNA and protein levels 
[11]. Separately, a study demonstrated that 1 μM ivermectin treatment inhibits the 
function of SIN3 [16], which is part of a complex that positively regulates Nanog 
and Sox2, leading to a decrease in mammospheres number [21]. Furthermore, 
ivermectin was reported to induce E-cadherin and Estrogen Receptor 1 expression 
and the restoration of tamoxifen sensitivity in a triple-negative breast cancer model. 
According to these observations, ivermectin has potential antitumor effects in 
triple-negative breast cancer [16]. Another study demonstrated a synergy between 
ivermectin with docetaxel or cyclophosphamide in estrogen receptor-negative 
breast cancer cells and a synergistic effect with tamoxifen in estrogen receptor-
positive breast cancer cell lines [22].
3.3 Liver cancer
In human combined hepatocellular-cholangiocarcinomas and intrahepatic 
cholangiocarcinomas (cHC-CCs and ICCs), there is robust YAP1 activation. YAP1 
is a transcriptional regulator of genes involved in cell proliferation and suppression 
of apoptotic genes, and itis inhibited in the Hippo signaling pathway which allows 
tumor suppression. Nuclear translocation of YAP1/TAZ also increases transcription 
of TGF-βs [23]. Thus, it is possible that coordinated targeting of YAP1/TAZ and 
TGF-β signaling may be a treatment for cHC-CCs and ICCs displaying dysregulated 





Onchocerciasis Myalgia, skin 
eruptions, joints 
swelling, limbs or face, 
itching, fever and cold
Skin pain and edema, 
arthralgia, bone pain, severe 
dizziness, high fever, dyspnea, 
and hypotension
NA
Filariasis Headache and nausea NA Encephalopathy




Adverse effects caused by Ivermectin.
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3.4 Cervical cancer
Ivermectin inhibits the viability of HeLa cells and induces a G1/S cell cycle arrest 
leading to apoptosis and morphological changes of DNA fragmentation and chro-
matin condensation of such cells. Additionally, ivermectin can significantly increase 
intracellular ROS content and inhibit the migration of HeLa cells [24].
3.5 Glioblastoma
Ivermectin inhibits the growth of glioma cells by inducing cell cycle arrest and 
apoptosis in vitro and in vivo [25]. Specifically, in glioblastoma and brain endo-
thelial cells, ivermectin has been reported to induce mitochondrial dysfunction. It 
inhibits cell growth and colony formation and blocks the enzymatic activity of the 
respiratory chain complex I, thereby decreases mitochondrial respiration, mem-
brane potential, and ATP levels while increasing the generation of superoxides that 
in turn induces cell death by caspase-dependent apoptosis. Additionally, ivermectin 
also inhibits angiogenesis at concentrations above 5 μM [12].
3.6 Leukemia and prostate cancer
The treatment of OCI-AML2 cells with ivermectin increased the concentra-
tion of intracellular chloride ions, leading to hyperpolarization of the plasma and 
mitochondrial membranes and ROS production [18]. In contrast, DU145 and PPC-1 
cells and primary normal hematopoietic cells that were resistant to ivermectin did 
not demonstrate changes in their plasma membrane potential when treated with up 
to 6 μM ivermectin. Moreover, the in vitro antitumor effect of ivermectin on various 
cancer cell lines at a concentration of 5 μM showed that DU145 is only minimally 
reduced in viability and clonogenic capacity, but when it is treated in combination 
with docetaxel cells demonstrated strong inhibition [22]. In myeloid leukemia cells 
ivermectin strongly synergizes with daunorubicin and cytarabine [18].
3.7 Colon and lung cancer
The WNT/TCF signaling pathway is constitutively active in many tumors and 
it regulates genes for cell growth and proliferation. Ivermectin can inhibit the 
WNT-TCF signaling pathway by decreasing cyclin D1, which is a direct target in this 
pathway and ivermectin also affects the phosphorylation of β-catenin, which leads 
to inhibition of proliferation and increased apoptosis in lung and colon tumor cells 
at concentrations above 5 μM [13].
4. Antitumor effects of ivermectin-animal data
In a wide-range of pre-clinical studies, rodent models of human xenografts of 
glioblastoma, leukemia, breast and colon carcinomas, as well as a variety of murine 
cell lines in syngeneic models have consistently shown ivermectin to possess robust 
antitumor effect at a median dose of 5 mg/Kg [12, 13, 15, 17, 18]. We present a 
review of some results of anticancer studies of ivermectin in animal below.
4.1 Glioblastoma
Two independent glioblastoma xenograft SCID mice models were established 
by subcutaneous injection of U87 or T98G cells, and the rodents were subsequently 
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treated with intraperitoneal ivermectin at 40 mg/Kg. The treated mice had demon-
strated significant tumor growth inhibition but maintained normal behavior and 
retained their weight [12]. A separate study using 3 mg/Kg of ivermectin showed 
a 50% decrease in tumor size and there was near complete regression of tumors at 
10 mg/Kg. Ki67 staining also confirmed that glioma cell proliferation was decreased 
in ivermectin-treated animals compared to controls [17].
4.2 Colon and lung cancers
Melotti et al. used H358 human metastatic lung bronchioalveolar carcinoma cells 
and DLD1 colorectal adenocarcinoma cells to test the antitumor effects of ivermec-
tin. The animals received intraperitoneal injections of cyclodextrin-conjugated 
ivermectin daily at 10 mg/kg after tumor establishment. Subsequently, it was found 
that tumors responded to ivermectin with a near 50% reduction of growth and a 
repressed lung cancer WNT-TCF signature and enhanced p21 levels [13].
4.3 Breast cancer
Ivermectin was evaluated in an orthotopic breast cancer model with human 
MDA-MB-231 cells subcutaneously injected in the mammary fat pad of NOD-SCID 
mice. Xenografts treated with ivermectin grew at a slower rate than those of the 
control group, and the size and weight of control tumors were macroscopically 
larger than that of ivermectin-treated tumors [15]. Another study tested JC murine 
breast cancer cells in Balb/c mice treated with a dose of 3 mg/Kg of ivermectin. 
Treatment reduced tumor size more than 60% with no changes in weight or 
behavior of the study animals when compared with controls [22]. Recently it was 
demonstrated the ivermectin at a dose of 5 mg/Kg induces immunogenic cell death 
hallmarks with large numbers of intratumoral CDA4+ and CD8+ T cells in a 4 T1 
murine tumor model. Thus, ivermectin turns cold tumors into hot ones which 
allows for marked synergy with check point inhibitor nivolumab, leading to major 
antitumor effects and most importantly, protective immunity [26].
4.4 Leukemia
Human leukemia (OCI-AML2 and K562) and murine leukemia (MDAY-D2) 
cells were injected subcutaneously into NOD/SCID mice which were subsequently 
treated with 3 mg/Kg (human equivalent dose of 0.240 mg/Kg) of ivermectin or 
control in water via oral gavage. Upon follow-up, the treated mice had up to 70% 
decrease in their tumor burden without any gross sign of organ toxicity, and treat-
ment led to increased apoptosis in OCI-AML2 xenografts [18]. It must be remarked 
that most of the in vivo studies to evaluate the antitumor effects of ivermectin dose 
ranging from 3 to 10 mg/Kg. These mice doses translate into human to 0.240 to 
0.810 mg/Kg which are clinically attainable [27].
5. Clinical experience with ivermectin
As mentioned above, there has been extensive clinical use of ivermectin as an anti-
parasitic, and the drug has been repurposed for use against other pathogens and non-
parasitic conditions in humans. However, despite considerable preclinical evidence 
of antitumor effects of ivermectin, it is curious that no clinical studies of ivermectin 
against cancer have been reported nor clinical trials launched. However, there is a case 
report on three children with refractory and heavily pretreated acute myeloblastyic 
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leukemia. In the three cases, ivermectin was at 1 mg/Kg either alone or in combina-
tion with Ara-C. Two of them had clinical improvement with durable stable disease 
in one, a and complete hematological response the second. The third one receiving 
ivermectin alone had no response. Though anecdotic, these data demonstrate that 
ivermectin can be safely administered at dosis five times higher the recommended 
dose of 0.200 mg/Kg, and that can show efficacy combined with cytotoxics [28].
Here, we briefly review the clinical experience with ivermectin as an antipara-
sitic as well as in other repurposed indications, with special attention to its toxicities 
and safety and its clinical pharmacology, the data of which can be a basis for future 
clinical trials of ivermectin against cancer.
5.1 Ivermectin use as anti-parasitic
Because of its broad spectrum applicability, ivermectin can be applied to treat 
onchocerciasis, lymphatic filariasis, strongyloidiasis, ascariasis, scabiasis, and 
enterobiasis. Since its discovery, ivermectin has been administered to millions of 
patients with the above parasitic infections around the world. Mild adverse effects 
of oral ivermectin therapy against certain parasites are common; many of them 
appear within 24-48 hours of the onset of therapy and are related to ivermectin 
dose as well as the microfilariae load in the skin in case of filiariasis [29, 30]. Some 
of these adverse effects include myalgia, skin rashes, joints swelling, limbs or face 
itching, fever, and chills. These effects are usually transient and do not require 
treatment [31, 32]. Moderate to severe effects are less common and may include skin 
edema with the presence of pain, arthralgia, severe dizziness, high fever, dyspnea, 
and hypotension (Mazzotti’s Reaction). It is known that such reaction is not related 
to the administration of Ivermectin but with the parasite amount present in the host 
[30, 31]. In addition to Mazzotti’s reaction, there have been cases of severe encepha-
lopathy that can be fatal in patients with onchocerciasis and filariasis after treat-
ment with ivermectin. The symptoms of encephalopathy include altered mental 
status, incontinence, and difficulty standing or walking 48 hours after ivermectin 
treatment [32, 33]. This effect is again probably due to the obstruction of the cere-
bral microcirculation due to the accumulation of paralyzed or killed parasites and 
not by ivermectin itself. [34, 35]. Also, toxic effects have been linked to ivermectin’s 
interaction with P-glycoprotein [8]. The absence of P-glycoprotein determines the 
accumulation of Ivermectin in the brain of transgenic mice who do not express it 
and dogs with impaired P-glycoprotein function (commonly a 4 base-pair deletion 
of the MDR-1 gene that produces a stop codon) have increased neurotoxicity to 
ivermectin [36]. Table 2 summarizes ivermectin’s adverse effects. The dose and 
schedules vary but human doses are standardized for approved indications within 
the range of 0.15 to 0.4 mg/Kg. For onchocerciasis, the recommended dose is 0.15 
mg/Kg once every 12 months, though patients with heavy ocular infection may 
require retreatment every 3 or 6 months. Filariasis usually requires a single dose of 










Onchocercosis patients 0.1–0.2 Oral 52.0 5.2 2.852
Healthy volunteers 0.35–0.6 Oral 87.0 4.2 1.444
Healthy volunteers 0.7–1.1 Oral 165.2 3.6 2.099
Healthy volunteers 1.4–2.0 Oral 247.8 4.2 4.547
Table 2. 
Pharmacokinetic data of Ivermectin in humans infected with parasites and in healthy volunteers.
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0.4 mg/Kg. In strongyloidiasis, a single dose of 0.2 mg/Kg is recommended; how-
ever, in immunocompromised (including HIV) patients, the treatment may require 
repeated administration (i.e. every two weeks) and continued suppressive therapy 
(i.e. once a month). A single dose of 0.2 mg/Kg is also used to treat ascariasis, while 
the same dose repeated once at two weeks is recommended for scabiasis [37].
Recently, there has been a growing interest in newer anti-parasitic indications 
of ivermectin such as against soil-transmitted helminths and malaria, hence doses 
above 0.4 mg/Kg are being evaluated for achieving higher plasma levels [38, 39].
An example is a pharmacokinetic trial using 18 mg ivermectin tablets in 54 
healthy adult volunteers to evaluate the safety of fixed regimens of 18 and 36 
mg [40]. A meta-analysis to investigate the safety of higher doses of ivermectin 
identified four studies for inclusion, and found no differences in the number of 
individuals experiencing adverse events at higher doses. A descriptive analysis of 
these clinical trials for a variety of indications also showed no difference in the 
severity of the adverse events between standard (up to 0.4 mg/Kg) and higher 
doses of Ivermectin (0.4-0.7 mg/Kg; 0.6 mg/Kg, and 0.8 mg/Kg). Only one trial 
showed an increase in transient and mild to moderate subjective ocular events such 
as transitory blurring of vision, itching or pain of the eye, and dyschromatopsia in 
the higher-dose group in a trial to treat onchocerciasis. Meanwhile, severe adverse 
events described as life-threatening, was reported in only one out of the four 
studies with one case of anaphylaxis at the standard dose and another case of QTc 
prolongation likely due to drug-drug interaction in a higher-dose group [41]. The 
result of this small meta-analysis is suggestive of relatively safety of higher doses of 
ivermectin.
5.2 Ivermectin’s potential as an anti-viral
Ivermectin exhibits anti-viral activity against viruses both in vitro and in vivo. 
The antiviral activity is thought to be related to tthe inhibition of nuclear trans-
location of viral proteins, facilitated by mammalian host importin also known 
as karyopherin α/β‐1 heterodimerization [42]. It is partially upon this basis that 
ivermectin has been tested as a treatment in the current COVID-19 pandemic. A 
recent meta-analysis and systematic review involving 629 COVID-19 patients from 
4 observational studies (3 with control arms and 1 without) found that adding iver-
mectin led to significant clinical improvement compared to control (OR=1.98, 95% 
CI: 1.11 - 3.53, p=0.02) [43]. however, the authors did caution on the interpretation 
of their analysis because the low quality of evidence, and it should be noted that one 
of the trials included in the analysis was subsequently retracted. Meanwhile, several 
randomized studies evaluating ivermectin against COVID-19 have recently been 
published. An Iranian trial demonstrated that a single 0.2 mg/Kg dose of ivermectin 
was well-tolerated in symptomatic COVID-19 patients, and dyspnea, cough and 
lymphopenia associated with COVID-19 were significantly improved [44]. In two 
other randomized trials, the time to viral clearance was statistically reduced. The 
doses and schedules in these two trials were ivermectin at a fixed 12 mg daily for 5 
days [45] and ivermectin at 0.1, 0.2, and 0.4 mg/Kg once at admission [46]. These 
were underpowered trials so that further evidence is still required to confirm the 
clinical usefulness of ivermectin under various COVID-19 clinical scenarios.
5.3 Other uses of ivermectin
Ivermectin possesses possible agonistic bioactivity against the γ-aminobutyric 
acid (GABA) receptor [47] and it was upon this premise that it was used in a 
patient with severe spasticity caused by spinal cord damage at a dose of 1.6 mg/
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Kg subcutaneously twice a week for 12 weeks. The patients had decreased spasm 
scores, suggesting that ivermectin may reduce spasticity in the spine without 
adverse effects at this high dose [48].
6.  Pharmacokinetics and dose considerations for ivermectin as cancer 
therapy
Due to its relatively long history of extensive use, the pharmacokinetics of 
ivermectin has been well studied. The oral route is the only approved for ivermectin 
administration in humans although it can be given subcutaneously and the intrave-
nous route of administration has also been investigated. Ivermectin is a fat-soluble 
compound and reaches a peak concentration 4-5 hours after oral administra-
tion, and it has a half-life of approximately 19 hours. After administration, it is 
subsequently extensively metabolized in human liver microsomes by cytochrome 
P-4503A4, converting the drug to at least ten metabolites, most of them hydroxyl-
ated and demethylated derivatives. Its excretion is mainly by the fecal route, and 
only 1% is excreted in the urine [49]. In healthy individuals and patients infected 
with onchocerciasis treated with a dose of 0.150 mg /Kg of Ivermectin, significant 
variability in pharmacokinetic parameters such as absorption, distribution, metab-
olism, and excretion is not observed [49].
The therapeutic dose for ivermectin as an anti-parasitic compound for human 
use is is between 0.1 and 0.4 mg/ Kg [4–7], resulting in an AUC of 1,444 μg/h/
mL. This drug exposure, which translates to a plasma concentration of 1.65 μM, is 
however less than concentrations of 5 μM or greater that has been found necessary 
to inhibit tumor cells in vitro In a phase I pharmacokinetic study done in healthy 
volunteers, it was demonstrated that doses up to 2 mg/Kg which leads to an AUC 
of 4,547 μg/h/mL can translate into a plasma concentration of 5 μM [50], thus the 
recommended dose for cancer therapy should likely be 2 mg/kg or higher.
7. Discussion
Currently, various efforts to facilitate the discovery of drug repurposing 
candidates for cancer and a large number of drug candidates do exist [51]. As an 
example, the Repurposing Drugs in Oncology (ReDO) Project, which is initiated 
by a non-profit international collaboration of researchers, clinicians, and cancer 
patient advocates whose goal is to find efficacious, minimally toxic, and affordable 
cancer treatments identified a total of 268 drugs that matched the following two 
criteria: i) the drug is licensed for non-cancer indications in at least one country in 
the world, and ii) the drug is the subject of one or more peer-reviewed publications 
showing a specific anticancer effect based on in vitro, in vivo, or clinical research in 
one or more malignancies. According to these criteria, ivermectin can be a potential 
repurposing candidate for cancer. Ivermectin has extensive preclinical in vitro and 
in vivo anticancer data and is thus an ideal candidate for clinical trials. An especially 
promising feature with ivermectin is that its anti-cancer concentration in vitro 
should be attainable clinically, inexpensively, and without undue toxicity.
8. Conclusion
Ivermectin has been administered to millions of patients as an anti-parasitic 
drug exhibiting a wide margin of clinical safety. There exists a large body of in vitro 
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and in vivo evidence demonstrating ivermectin’s anti-tumor potential, and ivermec-
tin’s anti-tumor efficacy can be demonstrated at concentrations that are clinically 
attainable based on clinical pharmacokinetics. We thus propose that ivermectin be 
considered urgently for clinical trials either as a single agent or in combination with 
existing antineoplastics for cancer.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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